Deciphera Pharmaceuticals

As of today, Deciphera is officially a member of ONO Pharma. Together, we remain focused on discovering, developing and delivering important new medicines to patients for the treatment of cancer. Learn more: https://lnkd.in/gbFyqhNg  

As of today, Deciphera is officially a member of ONO Pharma. Together, we remain focused on discovering, developing and delivering important new medicines to patients for the treatment of cancer. Learn more: https://lnkd.in/gbFyqhNg  

It’s official! Thanks to our people, Deciphera is proud to have earned #GreatPlaceToWork certification for the second year in a row in the United States and for the first time in Switzerland! Steve Hoerter, CEO, visited our Switzerland office last week to celebrate this great achievement with the team. This accomplishment reflects the hard work and commitment of our incredible team in fostering a positive and inclusive workplace culture.   Learn more about the Deciphera Difference and workplace culture here: https://lnkd.in/eVxsxaq7 #GreatPlaceToWork #GreatPlaceToWorkSwitzerland #GPTWCertified #TheDecipheraDifference  

It’s official! Thanks to our people, Deciphera is proud to have earned #GreatPlaceToWork certification for the second year in a row in the United States and for the first time in Switzerland! Steve Hoerter, CEO, visited our Switzerland office last week to celebrate this great achievement with the team. This accomplishment reflects the hard work and commitment of our incredible team in fostering a positive and inclusive workplace culture.   Learn more about the Deciphera Difference and workplace culture here: https://lnkd.in/eVxsxaq7 #GreatPlaceToWork #GreatPlaceToWorkSwitzerland #GPTWCertified #TheDecipheraDifference  

Today we announced that results from the MOTION pivotal Phase 3 study of vimseltinib are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, and have been published in The Lancet. Read the press release here: https://lnkd.in/ed7TGdyc

Last week on May 21st, World Day for Cultural Diversity, we came together for a virtual social hour to connect and celebrate the richness that our unique cultural backgrounds bring to our work at Deciphera. Our incredible team comprises individuals from diverse backgrounds and talents, all united by our passion to improve the lives of people living with cancer. Diversity and Inclusion are integral to innovation and progress at Deciphera, and we are committed to fostering an inclusive workplace for all. #GreatPlaceToWork #TheDecipheraDifference 

This Memorial Day, we remember and honor those who made the ultimate sacrifice for our nation. Their courage and dedication will not be forgotten. #MemorialDay

We are excited to announce that Deciphera has entered into an agreement to be acquired by ONO Pharmaceutical for $2.4 billion. Together, we will accelerate our shared vision to deliver innovative new drugs and serve patients around the world. Deciphera’s specialized capabilities in kinase drug discovery, our well-established commercial and sales platforms throughout the United States and Europe, and global clinical development capabilities will enable ONO to build a robust presence in oncology. As part of ONO, we will be positioned to advance our work to bring QINLOCK and potentially vimseltinib to more people, sooner than we could as an independent company. For more details, please view the news release and other important information here: https://lnkd.in/gE69XdJ9

Deciphera is participating in a fireside chat at the Stifel Financial Corp. 2024 Virtual Targeted Oncology Forum today at 11:30 AM ET. View the webcast here: https://lnkd.in/dYZ59Js

Deciphera is presenting preclinical data for DCC-3084 at the American Association for Cancer Research (AACR) Annual Meeting 2024, on Sunday, April 7 in San Diego, CA. #AACR24